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Abstract
Background: Intensive chemotherapy frequently results in gut toxicity, indicated by oral and intestinal mucositis, resulting
in poor treatment outcomes and increased mortality. There are no effective preventive strategies against gut toxicity and
the role of diet is unknown.
Objective:We hypothesized that the severity of chemotherapy-induced gut toxicity in early life is diet-dependent, and that
intake of bovine colostrum (BC) provides better gut protection than an artificial milk replacer (MR).
Methods: A total of 37 3-d-old pigs received for 6 d either intravenous saline control or myeloablative treatment with
busulfan and cyclophosphamide, and were fed either BC or MR, resulting in the following 4 treatments (n = 8–10/group):
bovine colostrum plus saline control (Ctr-BC), milk replacer plus saline control (Ctr-MR), bovine colostrum plus busulfan
and cyclophosphamide chemotherapy (BUCY-BC), and milk replacer plus busulfan and cyclophosphamide chemotherapy
(BUCY-MR). The gut was collected for analysis 11 d after the start of chemotherapy.
Results: Relative to the control groups, both busulfan and cyclophosphamide chemotherapy (BUCY) groups showed signs of
gut toxicity, with oral ulcers, reduced intestinal dimensions, and hematologic toxicity. Diet type did not affect mucosal structure
on day 11, but BUCY-BC pigs had less vomiting than BUCY-MR pigs (1 of 10 vs. 10 of 10, P < 0.05). Markers of intestinal
functionwere higher (up to 20-fold greater galactose absorption and 2–3-fold greater brush border enzyme activity, all P < 0.05),
and tissue inflammatory cytokine concentrations and serum liver enzyme values were lower in BUCY-BC than in BUCY-MR
pigs (30–50% reductions in interleukin 6 and 8, aminotransferase, and bilirubin concentrations, P < 0.05). Gut colonization was
not significantly affected except that BUCY pigs had lower microbial diversity with a higher abundance of Lactobacilli.
Conclusion: BC may reduce gut toxicity during myeloablative chemotherapy in piglets by preserving intestinal function and
reducing inflammation. Whether similar effects occur in children remains to be tested. J Nutr 2015;145:1472–80.
Keywords: mucositis, gastrointestinal toxicity, bovine colostrum, chemotherapy, piglets
Introduction
The introduction of intense chemotherapy regimens based on
risk stratification and hematopoietic stem cell transplantation
(HSCT)9 has led to improved disease control and higher survival
rates in children with acute leukemia. Aggressive treatments may
also lead to increased toxicity and more complications, together
with increased risk of graft-versus-host disease, after HSCT (1,
2). The treatment-related mortality in childhood acute lympho-
blastic leukemia, acute myeloid leukemia, and HSCT is 2–5%,
10–15%, and 10–30%, respectively, and infections play a major
role (3–5). Among the factors that are believed to contribute to
this increased infection risk is mucosal barrier injury in the
alimentary tract, potentially leading to increased translocation
of bacteria and endotoxins from the gut (6). Gastrointestinal
9 Abbreviations used: BC, bovine colostrum; BUCY, busulfan and cyclophos-
phamide chemotherapy; BUCY-BC, bovine colostrum plus busulfan and cyclo-
phosphamide chemotherapy; BUCY-MR, milk replacer plus busulfan and
cyclophosphamide chemotherapy; Ctr-BC, bovine colostrum plus saline control;
Ctr-MR, milk replacer plus saline control; HSCT, hematopoietic stem cell
transplantation; MR, milk replacer; NEC, necrotizing enterocolitis; OTU, opera-
tional taxonomic unit; PCoA, principal coordinate analysis.
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toxicity is a common complication of cytotoxic therapy and the
incidence among pediatric leukemia patients is 40–100%, depend-
ing on disease, type of cytotoxic drug, dose, dosing schedule, and
individual factors (7). Patients with mucositis also suffer from
severe pain and reduced quality of life. Unfortunately, it has been
difficult to reduce gastrointestinal toxicity without reducing the
intensity of treatment, thereby increasing the risk of relapse (8).
Children tolerate relatively intense treatment with chemotherapy
but it is not clear whether developing organs, including the
gastrointestinal tract, are more or less sensitive to chemotherapy-
induced damage in early life, and how dietary factors may
modulate this sensitivity (9, 10).
Bovine colostrum (BC) contains high concentrations of many
bioactive compounds, such as TGF-b and insulin-like growth
factors 1 and 2, that may stimulate gut growth and function and
induce mucosal protection via immunomodulatory effects (11–
13). Preclinical animal studies show that gastrointestinal toxicity
may be affected by nutrition, suggesting that dietary treatment
may be a possible adjunct strategy to limit gastrointestinal toxicity
(14). In preterm pigs, BC is known to reduce the bacteria-
dependent, inflammatory lesions that are characteristic of necro-
tizing enterocolitis (NEC) in preterm infants (15, 16). Cytotoxic
chemotherapymay also change the gutmicrobiota in both humans
(17) and animal models (18). In cancer patients, microbiota
changes have been correlated with gut toxicity (19) and, in some
experimental rat models, alleviation of chemotherapy-induced
symptoms is observed after administration of probiotics (20–22).
Under germ-free conditions in mice, the response to chemotherapy
is either reduced (23) or increased (24). The gut microbiota is
relatively unstable in early life but it remains unclear if and how
this may affect the response to chemotherapy and to diets with
different antibacterial or anti-inflammatory activities in the gut.
We hypothesized that BC would reduce gastrointestinal dam-
age caused by cytotoxic myeloablative chemotherapy. We used
young milk-fed piglets because we specifically wished to study the
intestinal response to chemotherapy in early life. However, liquid
milk-based diets are often required for all age groups of patients
with severe chemotherapy-induced oral mucositis or gastrointes-
tinal toxicity. We investigated the response in piglets after a
clinically applied regimen consisting of busulfan and cyclophos-
phamide chemotherapy (BUCY).Our key endpointswere hematology,
liver enzymes, gut microbiota, and the structure, function, and
inflammatory status of the small intestine.
Methods
Experiment setup. Thirty-seven 3-d-old crossbred pigs (Large White3
Danish Landrace) were allocated to be fed either BC or milk replacer
(MR), and further allocated to receive either intravenous saline or
chemotherapy with busulfan plus cyclophosphamide. Accordingly, the
study included the following 4 treatments: bovine colostrum plus
busulfan and cyclophosphamide chemotherapy (BUCY-BC, n = 10), milk
replacer plus busulfan and cyclophosphamide chemotherapy (BUCY-
MR, n = 10), bovine colostrum plus saline control (Ctr-BC, n = 8), and
milk replacer plus saline control (Ctr-MR, n = 9). An overview of the
study design is shown in Supplemental Figure 1. The BUCYpigs received
4 d of busulfan treatment (total dose 12.8 mg/kg) and 2 d of
cyclophosphamide treatment (total dose 120 mg/kg) over 6 consecutive
days. Diet intervention was initiated on day 0, whereas the cytotoxic
chemotherapy regimen was initiated on day 1 and pigs were killed and
sampled on days 10–11, or earlier if predefined humane endpoints
required killing before the end of the protocol. The humane endpoints
were defined as severe pain that could not be relieved by paracetamol and
buprenorphine, signs of severe toxicity (continued shedding of blood or
mucosa per rectum), and signs of sepsis (cyanosis, progressing respira-
tory distress, and lethargy). On days 10–11, pigs were anesthetized,
blood subsequently was collected by cardiac puncture, and pigs were
killed by intracardial injection of sodium pentobarbital, 200 mg/kg. Pigs
that died or were killed before day 9 were excluded and not sampled. A
detailed description of the BUCY-BC protocol used in this study has been
published previously (25), with an explanation of surgical and anesthetic
procedures, supporting drugs, hyperhydration, and uromitexan treat-
ment to prevent cyclophosphamide-induced hemorrhagic cystitis and
toxic response to BUCY.
Housing and feeding. Pigs were kept in individual cages and fed
11 times/d (15 mL/kg, total 165 mL  kg21  d21). Pigs were allowed
voluntary feeding from individual troughs, but were supplemented with
orogastric feeding if appetite was reduced to reach the predetermined
daily volume. If a pig vomited during or after feeding, the feeding volume
was reduced to 50% and gradually increased to reach the target volume
over the following 6–12 h. BC was collected from the first milking within
24 h after parturition at a local Danish dairy farm (Danish Red cows),
stored at 220C, and sterilized by g-irradiation (10 kilograys;
Sterigenics). The macronutrient composition of the colostrum product
was 5340 kJ/L energy, 103 g/L protein, 36 g/L carbohydrate, and 55 g/L
fat, consistent with earlier reported values for BC (13, 26). The MR was
prepared from the products Pepdite (60 g/L, powdered enteral nutrition
with nonmilk-derived low molecular weight peptides, essential amino
acids, carbohydrate, fat, vitamins, and minerals; Nutricia), Lacprodan
(50 g/L, whey protein; Arla Foods Ingredients), Miprodan (50 g/L,
casein; Arla Foods Ingredients), Calogen (50 g/L, long-chain TG fat
emulsion; Nutricia), Liquigen (80 g/L, medium-chain TG from fraction-
ated coconut oil; Nutricia), and Seravit-SHS (12 g/L, vitamins and trace
elements; Nutricia). Similar products and ingredients are commonly used
for hospitalized children requiring enteral nutrition formulas. The
macronutrient composition in the finalMRwas 5291 kJ/L energy, 96 g/L
protein, 40 g/L carbohydrate, and 79 g/L fat.
Clinical endpoints. Body weight and clinical signs of toxicity (presence
of vomiting or diarrhea) were recorded daily. Oral ulcers representing
oral mucositis were recorded at tissue collection. Blood samples were
drawn before the first infusion of busulfan on day 1 and again on days 4,
7, 9, and 11 for complete hematologic blood count. A biochemical
profile was analyzed in serum on days 1, 7, and 11. Blood hematology
and biochemical profile were analyzed with the use of the Advia 2120
Hematology System (Siemens).
Intestinal nutrient absorption, permeability, and serum citrulline.
To evaluate the in vivo nutrient absorption capacity of the apical sodium-
glucose linked transporter 1, a galactose absorption test was performed
on days 1, 7, and 10 as described elsewhere (27). To evaluate intestinal
permeability, an enteral bolus of lactulose (5%, vol:vol) and mannitol
(5%, vol:vol) was administered 3–5 h before tissue collection. Urine was
sampled directly from the bladder before tissue collection. Concentrations
of lactulose and mannitol were measured as previously described (27).
Circulating concentrations of the amino acid citrulline were mea-
sured to evaluate enterocyte mass as a marker of small intestinal toxicity
during the study. Citrulline has been shown to correlate with intestinal
mass (28), and low concentrations of citrulline correlate with clinical
scores of intestinal toxicity (1). At days 1, 7, and 11, serumwas collected
and concentration of citrulline was quantified as previously described
(29), with some modifications. Briefly, the serum samples were processed
with the use of a Sirocco protein precipitation plate (Waters) and Oasis
HLB Extraction Plate (Waters) then separated on a graphitic carbon
column (Thermo Scientific) in an ultra-performance LC tandem quad-
rupole detector MS (Waters) with L-citrulline-4,4,5,5-d4 (Sigma-
Aldrich) as internal standard. Quantification of citrulline was carried
out with the use of QuanLynx (Waters).
Organ dimensions, histology, and tissue analyses. The small
intestine, from the pyloric sphincter to the ileocecal junction, was removed
and its length was recorded. The intestine was divided into 3 segments of
equal length, designated proximal, middle, and distal regions, and each
region was weighed. Samples from each region were collected for
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histologic evaluation, with villus height and crypt depth in formaldehyde
fixated tissue samples measured, mounted in paraffin, sliced, and stained
with hematoxylin and eosin as described elsewhere (25). A 10 cm section
from the middle of the distal region was removed for measurement of the
mucosal proportion, as described previously (30). Other organs (stomach,
colon, liver, kidneys, spleen, heart, and lungs) were removed and their wet
weights recorded. Finally, a piece of sternum containing bone marrow
was collected and bone marrow cellularity was evaluated by a blinded
pathologist as described previously (25).
Snap-frozen intestinal samples were later homogenized in 1% Triton
X-100 and assayed for intestinal activity of disaccharidases (sucrase,
maltase, and lactase) and peptidases (aminopeptidase N, aminopeptidase
A, and dipeptidyl peptidase IV), with the use of specific substrates as
previously described (30, 31). For cytokine analyses, a protease inhibitor
cocktail was added to the homogenization solution. Cytokine concentra-
tions were measured with the use of ELISA kits (R & D Systems) targeted
against IL-8, IL-6, IL-1b, and TNF-a as described elsewhere (25).
Gut microbiota. From luminal content collected from the distal small
intestine, DNAwas purified with the use of the Maxwell 16 Instrument
(Promega Corporation), following the manufacturers protocol for the
low elution volume blood DNA system, but with additional lysozyme
treatment and bead beating with stainless steel beads for 2 min/20 Hz in
a tissue lyser (Qiagen). The V4 and V5 regions of the 16S ribosomal
RNA gene were PCR amplified from each sample with the use of
barcoded primers: 519F (5#-CAGCAGCCGCGGTAATAC-3#) and 926R
(5#-CCGTCAATTCCTTTGAGTTT-3#) and analyzed for quantity and
quality in an Agilent 2100 Bioanalyzer (Agilent Technologies) with the use
of an Agilent RNA 1000 Nano Kit. An amount of 50 ng DNA from each
sample was pooled for library preparation with molecular identifier for 1-
region 454 sequencing on GS FLX Titanium PicoTiterPlates (70675) with
the use of a GS FLX Titanium Sequencing Kit XLR70 (Roche Diagnostics).
Library construction and 454 pyrosequencingwas carried out at theNational
High-Throughput DNA Sequencing Centre, University of Copenhagen.
Data were analyzed with the use of the Quantitative Insight Into
Microbial Ecology open source software package (32). Raw data
underwent denoising, chimera filtering, and operational taxonomic unit
(OTU) picking, as previously described (33), and the remaining high-
quality sequences were clustered at 97% relatedness with the use of
UCLAST (34). Representative sequences from each cluster were aligned
with PyNAST (35), subjected to the Ribosomal Database Project–based
16S ribosomal RNA gene annotation. Alpha diversity was calculated
(observed species) for OTU tables unified to 2000 sequences per sample.
Principal coordinate analysis (PCoA) plots were generated with the
jackknifed beta diversity workflow based on 10 distance metrics calcu-
lated with the use of 10 subsampled OTU tables and 85% of sequences
taken for each jackknifed subset. Group differences in the PCoA plots
were evaluated by analysis of similarities with the use of weighted and
unweighted UniFrac distance metrics based on rarefied OTU tables (1000
reads/sample). Group differences in relative taxa abundances at phylum
and genus level were calculated and verified with Metastats (36) based on
1000 permutations of random combinations of group pairs. Differences in
the most dominating OTUs were tested with the use of the lmer function
of mixed model analysis in R version 3.0.1 with treatment, diet, and
presence of mucositis as fixed variables.
Statistical methods. Categorical outcomes (vomiting, diarrhea, and oral
mucositis) were analyzed with the use of logistic regression on the overall
incidence. The daily growth rates were calculated as weight gained
(grams) over 2 d, divided by body weight (kilograms) on the first of the
2 d. Continuous data were analyzed with the use of 2-factor ANOVA,
with treatment (BUCY or control) and diet (BC or MR) as independent
categorical variables. Repeated measurements (growth rate, blood hema-
tology, serum biochemistry, plasma galactose, serum citrulline, villus
height, crypt depth, and brush border enzymes) were analyzed with the
use of mixed models, with day or intestinal segment as additional fixed
effects and pig as a random effect. Normality was assessed by means of
standardized residuals and Box-Cox transformed to account for variance
heterogeneity, when necessary. Cytokine IL-6 and IL-1b concentrations
were analyzed with the use of a Tobit model to account for measurements
below the detection limit of the assay. Spearmans rank correlation
coefficient was used to investigate associations between plasma concen-
trations of citrulline and relative intestinal weight at the end of the study.
Differences between groups were evaluated with the use of post hoc t tests
without multiplicity adjustment of P values. P values < 0.05 were
considered significant. All values presented are arithmetic means6 SEMs
unless otherwise stated. All statistical analyses were performed in Stata/IC
12.1 (StataCorp).
Results
Clinical endpoints. Forty percent (8 of 20) of the BUCY pigs
had to be killed before the predetermined end of the protocol on
days 10–11, 2 BUCY-BC and 6 BUCY-MR pigs. Mean growth
rates during the first 6 d were similar among the groups. After the
BUCY treatment (days 7–11), growth rates decreased, resulting in
negative growth rates in the 2 BUCY groups, most pronounced in
FIGURE 1 Clinical variables in piglets treated with intravenous
BUCY or saline and fed either BC or MR throughout the study. Growth
rates throughout the entire study (A) and growth rates during and after
the BUCY treatment, days 1–6 and days 7–11, respectively (B), and
the overall incidence of diarrhea (C) and vomiting (D). Growth rates are
means6 SEMs and incidences are overall percentage of affected pigs
in each group throughout the study; BUCY-BC, n = 10; BUCY-MR, n =
10; Ctr-BC, n = 8; and Ctr-MR, n = 9. Labeled means (at a time)
without a common letter differ, P , 0.05. BC, bovine colostrum;
BUCY, busulfan and cyclophosphamide chemotherapy; BUCY-BC,
bovine colostrum plus busulfan and cyclophosphamide chemotherapy;
BUCY-MR, milk replacer plus busulfan and cyclophosphamide che-
motherapy; Ctr-BC, bovine colostrum plus saline control; Ctr-MR, milk
replacer plus saline control; MR, milk replacer.
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the BUCY-MR pigs. Calculated for the entire 1–11 d period,
growth rates in the 2 BUCY groups were lower than in the Ctr-
MR pigs, and there was no effect from BC on growth rates in
BUCY-treated pigs (Figure 1A and B).
The overall diarrhea incidence was similar among BUCY-BC
and BUCY-MR pigs, and higher than in Ctr-MR pigs, with
intermediate values in Ctr-BC pigs (Figure 1C). Vomiting was
observed only in the chemo groups, and it wasmost pronounced in
BUCY-MR pigs (Figure 1D). Among pigs that were alive after day
8, oral ulcers were observed in 4 of 5 BUCY-MR pigs vs. 4 of 8
BUCY-BC pigs, whereas oral ulcers were absent in all control pigs.
Organ toxicities and blood chemistry and hematology.
The BUCY treatment resulted in bone marrow aplasia in all
BUCY pigs, with no effect from diet on mean cellularity (>10%
for the 2 BUCY groups vs. 76% for the 2 control groups, P <
0.001). Supporting these findings, relative spleen weight was
lower in the 2 BUCY groups (1.8–2.2 g/kg) than in Ctr-MR (3.36
0.3 g/kg) and Ctr-BC (4.3 6 0.2 g/kg) pigs (both P < 0.05), and
there was no effect from diet in the 2 BUCY groups. Corre-
spondingly, the number of circulating blood cells (neutrophils,
lymphocytes, platelets, and reticulocytes) was reduced in all
BUCY pigs compared with control (Supplemental Figure 2A–D).
BC delayed the reduction in platelet counts in BUCYpigs (day 9,
P < 0.05) (Supplemental Figure 2D) but had no effect on
leukocytes and reticulocytes. In controls, BC increased the
lymphocyte counts by the end of the experiment (day 11, P <
0.05) (Supplemental Figure 2B). Mean red blood cell counts were
similar among the groups throughout the study (data not shown).
Indications of chemotherapy-induced liver damage were eval-
uated by serum concentrations of transaminases and bilirubin. On
FIGURE 2 Longitudinal serum biochemistry values in piglets
treated with intravenous BUCY or saline and fed either BC or MR.
ALAT (A), ASAT (B), and bilirubin (C). Values are means 6 SEMs;
BUCY-BC, n = 6–10; BUCY-MR, n = 3–10; Ctr-BC, n = 6–8; and Ctr-
MR, n = 5–8. A minor horizontal jitter has been applied to prevent
overlapping and improve visual appearance and identification of group
values. Labeled means (at a time) without a common letter differ, P ,
0.05. ALAT, alanine aminotransferase; ASAT, aspartate aminotrans-
ferase; BC, bovine colostrum; BUCY, busulfan and cyclophosphamide
chemotherapy; BUCY-BC, bovine colostrum plus busulfan and cyclo-
phosphamide chemotherapy; BUCY-MR, milk replacer plus busulfan
and cyclophosphamide chemotherapy; Ctr-BC, bovine colostrum plus
saline control; Ctr-MR, milk replacer plus saline control; MR, milk
replacer.
FIGURE 3 Intestinal morphology and mass in piglets treated with
intravenous BUCY or saline and fed either BC or MR. Villus height (A)
and crypt depth (B) in samples from the proximal, middle, and distal
small intestine, total small intestinal weight relative to body weight
(C), and serum citrulline concentrations measured longitudinally during
the 11 d protocol as a marker of enterocyte mass (D). Values are
means 6 SEMs; BUCY-BC, n = 4–9; BUCY-MR, n = 4–6; Ctr-BC, n =
4–8; and Ctr-MR: n = 6–8. A horizontal jitter has been applied to
prevent overlapping and improve visual appearance and identification
of group values for the longitudinal data. Labeled means (at a time or
in a region) without a common letter differ, P , 0.05. BC, bovine
colostrum; BUCY, busulfan and cyclophosphamide chemotherapy;
BUCY-BC, bovine colostrum plus busulfan and cyclophosphamide
chemotherapy; BUCY-MR, milk replacer plus busulfan and cyclophos-
phamide chemotherapy; Ctr-BC, bovine colostrum plus saline control;
Ctr-MR, milk replacer plus saline control; MR, milk replacer.
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days 7 and 11, alaninine aminotransferase and aspartate amino-
transferase concentrations were markedly elevated in the BUCY-
MRpigs relative to the BUCY-BC pigs and controls (Figure 2Aand
B). A later and more moderate BUCY-related elevation of these
liver enzymes was observed in the BUCY-BC group comparedwith
the Ctr-BC pigs. Likewise, BUCY pigs showed greatly elevated
bilirubin concentrations on day 11 (Figure 2C), and concentra-
tions were even higher in BUCY-MR pigs than in BUCY-BC pigs.
Intestinal structure, digestive function, and inflammatory
markers. Chemotherapy generally reduced the villus height and
crypt depth (especially in the proximal region), but these
variables were not affected by diet (Figure 3A and B), despite
the fact that small intestinal mass tended to be higher in Ctr-MR
pigs than in Ctr-BC pigs (P = 0.06). Supporting the histomor-
phologic findings, relative intestinal weight was reduced in both
BUCY groups compared with controls (Figure 3C). Colostrum
did not affect intestinal length, colon weight, or intestinal
mucosal proportions (data not shown). Serum citrulline con-
centrations were equal among all groups on day 1 (18.9 6 1.5
mg/mL) and showed limited change with time or treatment,
except that values for the Ctr-MR pigs were higher than for the
other 3 groups from day 7 to day 11 (Figure 3D). For BUCYpigs,
a positive correlation was found between citrulline and relatively
small intestinal weight on day 11 (r = 0.83, P < 0.01).
Active intestinal absorption of hexose via sodium-glucose
linked transporter 1 was investigated by measuring plasma
galactose after an oral bolus of galactose. In MR pigs, chemo-
therapy treatment led to a pronounced decrease in galactose
absorption, whereas in pigs treated with BC, absorption of
galactose was maintained despite chemotherapy (Figure 4A).
After a galactose bolus on days 7 and 10, BUCY-BC pigs reached
5–7-fold higher concentrations of galactose than BUCY-MR pigs,
and values were similar to those in control pigs. Intestinal
permeability was assessed with the lactulose/mannitol test. The
lactulose-to-mannitol ratio tended to be increased in BUCY-
treated pigs vs. control pigs (P = 0.05), but there was no effect
from diet (Figure 4B). This may be explained in part by the low
sample size for analyses. There were difficulties in sampling urine
from many of the pigs at autopsy and only 17 of 37 pigs had
sufficient urine for analysis. Similar difficulties in collecting
sufficient colon content and blood also influenced the number of
represented pigs for other analyses.
FIGURE 4 Intestinal function in vivo in piglets treated with intravenous
BUCY or saline and fed either BC or MR. Absorption of galactose
measured in plasma 20 min after an enteral galactose bolus on days 1, 7,
and 11 (A) and intestinal permeability assessed with the urinary lactulose-
to-mannitol ratio sampled 3h after an enteral bolus solution with lactulose
and mannitol (B). Values are means 6 SEMs; BUCY-BC, n = 2–5; BUCY-
MR, n = 3–7; Ctr-BC, n = 3–5; and Ctr-MR, n = 4–7. A horizontal jitter has
been applied to prevent overlapping and improve visual appearance and
identification of group values for the longitudinal data. Labeled means (at a
time) without a common letter differ, P , 0.05. BC, bovine colostrum;
BUCY, busulfan and cyclophosphamide chemotherapy; BUCY-BC, bovine
colostrum plus busulfan and cyclophosphamide chemotherapy; BUCY-
MR, milk replacer plus busulfan and cyclophosphamide chemotherapy;
Ctr-BC, bovine colostrum plus saline control; Ctr-MR, milk replacer plus
saline control; lac, lactulose; man, mannitol; MR, milk replacer.
FIGURE 5 Activity of brush border
enzymes in the proximal, middle, and
distal regions of small intestinal tissue
from piglets treated with intravenous
BUCY or saline and fed either BC or
MR. Lactase (A), maltase (B), sucrase
(C), ApA (D), ApN (E), and DPP-IV (F).
Values are means 6 SEMs; BUCY-
BC, n = 9; BUCY-MR, n = 5; Ctr-BC,
n = 8; and Ctr-MR, n = 8. Labeled
means (in a region) without a com-
mon letter differ, P , 0.05. ApA,
aminopeptidase A; ApN, aminopepti-
dase N; BC, bovine colostrum; BUCY,
busulfan and cyclophosphamide
chemotherapy; BUCY-BC, bovine
colostrum plus busulfan and cyclo-
phosphamide chemotherapy; BUCY-
MR, milk replacer plus busulfan and
cyclophosphamide chemotherapy;
Ctr-BC, bovine colostrum plus saline
control; Ctr-MR, milk replacer plus
saline control; DPP-IV; dipeptidyl pep-
tidase IV; MR, milk replacer.
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The digestive function of enterocytes was assessed by
measuring the activity of brush border enzymes. Generally, the
enzymes examined showed reduced activity in pigs treated with
chemotherapy and the reduction was less pronounced in BC
pigs. Thus, disaccharidase activities (sucrase, lactase, and
maltase) were 200–300% higher in the 2 groups of BC pigs
(control and BUCY) than in MR pigs (Figure 5A–C). Amino-
peptidase activities (aminopeptidase N and aminopeptidase A)
showed the same pattern, although the differences between
BUCY-BC and BUCY-MR pigs were not as pronounced. Activity
of dipeptidyl peptidase IV was increased 100% in BUCY-BC vs.
BUCY-MR pigs in the distal region (Figure 5D–F).
To examine the effect of colostrum on chemotherapy-induced
mucosal inflammation, inflammatory cytokines were mea-
sured in the intestinal tissue. Generally, chemotherapy tended
to increase the tissue concentrations of the cytokines, especially
IL-8 and IL-6, albeit to different degrees. Thus, concentrations
of IL-8 in the distal intestine, and of IL-6 in the proximal
intestine, were higher in BUCY-MR pigs than in the other
groups (P < 0.05, Figure 6A and B). The same pattern was seen
for IL-8 in the proximal region and IL-6 in the distal region,
although these differences did not reach statistical significance
(Figure 6A and B). Concentrations of IL-1b and TNF-a were
generally low, and no differences were found between groups
(Figure 6C and D).
Gut microbiota. Adequate DNA yield from the distal small
intestinal content for subsequent 454 pyrosequencingwas obtained
from 29 pigs (BUCY-BC, n = 8; BUCY-MR, n = 5; Ctr-BC, n = 8;
and Ctr-MR, n = 8). After quality control, a total of 247,710
sequences remained with a mean of 8542 6 1527 sequences per
sample (ranging from 721 to 38,310 sequences per sample). Seven
phyla were identified, along with a total of 63 OTUs (genus level),
with amean of 13.46 0.8 different OTUs per sample. The data set
was strongly dominated by Lactobacillus, representing 84%, and
Escherichia, representing 9% of the total sequences. Chemother-
apy or diet did not significantly modify the microbiota composition
in the distal small intestine as tested by PCoA and analysis of
similarities. However, the relative distribution of the most domi-
nating OTUs (Figure 7A) showed that Lactobacillus was substan-
tially more abundant in BUCY-pigs than in control pigs, whereas
diet had no significant effect. Escherichia, the second most
dominating OTU, was not affected by chemotherapy or diet,
whereas Lactococcus, the third most dominating OTU, was
significantly more abundant in MR than in BC pigs (P < 0.05,
Figure 7A). Microbial diversity was significantly lower in the
BUCY groups than in control (P < 0.05, Figure 7A), with a trend to
higher diversity in MR than in BC pigs (P = 0.08). No significant
differences were found between BUCY-BC and BUCY-MR pigs.
FIGURE 6 Proinflammatory cytokine concentrations in the proximal and
distal regions of small intestinal tissue from piglets treatedwith intravenous
BUCY or saline and fed either BC or MR. IL-8 (A), IL-6 (B), IL-1b (C), and
TNF-a (D). Values are means6 SEMs; BUCY-BC, n = 9; BUCY-MR, n = 5;
Ctr-BC, n = 8; and Ctr-MR, n = 8. Values below the detection limit were set
to the lowest value of detection and analyzed with the Tobit method for
IL-6 and IL-1b. Labeled means (in a region) without a common letter differ,
P , 0.05. BC, bovine colostrum; BUCY, busulfan and cyclophosphamide
chemotherapy; BUCY-BC, bovine colostrum plus busulfan and cyclophos-
phamide chemotherapy; BUCY-MR, milk replacer plus busulfan and
cyclophosphamide chemotherapy; Ctr-BC, bovine colostrum plus saline
control; Ctr-MR, milk replacer plus saline control; MR, milk replacer.
FIGURE 7 Relative distribution
of dominating bacteria (genus level)
in the colon content of piglets
treated with intravenous BUCY or
saline and fed either BC or MR.
Distribution among all 4 treatment
groups (A) and distribution between
BUCY pigs with and without oral
mucositis (B). The data are based
on 454 pyrosequencing, in which
Lactobacillus accounts for .70%
and .85% of the sequences in the
control pigs and BUCY pigs, respec-
tively. BUCY-BC, n = 8; BUCY-MR,
n = 5; Ctr-BC, n = 8; and Ctr-MR, n =
8. BC, bovine colostrum; BUCY, busulfan and cyclophosphamide chemotherapy; BUCY-BC, bovine colostrum plus busulfan and cyclophosphamide
chemotherapy; BUCY-MR, milk replacer plus busulfan and cyclophosphamide chemotherapy; Ctr-BC, bovine colostrum plus saline control; Ctr-MR, milk
replacer plus saline control; MR, milk replacer.
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Oral mucositis did not affect the relative bacterial distribution of
the small intestine, although BUCYpigs with oral mucositis tended
to have more Escherichia than BUCY pigs with no signs of oral
mucositis (8.8% vs. 0.15%, P = 0.05, Figure 7B).
Discussion
Using piglets as a model for children subjected to chemotherapy,
we have shown that BC improves the intestinal response to
myeloablative chemotherapy vs. a diet based on commercially
available products for enteral nutrition formulas. This is important
because gastrointestinal toxicity after myeloablative chemother-
apy is closely associated with treatment-related morbidity and
mortality (37). Preventive strategies against mucositis are often
limited to pain management, improved oral hygiene, and prophy-
laxis against bacterial and fungal infections (38). The pathophys-
iology of gut toxicity is poorly understood but may involve
apoptosis, impaired proliferation, inflammation, and increased
intestinal permeability (39), together with effects on mucosal
metabolic pathways (40), brush border enzyme activities, and
nutrient absorption (41). Gastrointestinal toxicity may be mod-
ulated by diet (42), but because of the limited availability of tissues
from humans, how diet affects acute gut toxicity remains largely
unknown. Further, there is limited or no information available
from animal models that mimic the developing state of the
intestine in infants and children.
In this study, milk-based diets were fed over the entire period
from before treatment to after the peak of cytotoxic damage that
typically occurs within 3–6 d after initiation of chemotherapy
(43). Using this protocol, we demonstrated that piglets subjected
to a standard BUCY treatment had intestinal atrophy, increased
cytokine concentrations, and impaired intestinal function (brush
border enzymes and nutrient absorption) at days 10–11, in
addition to the clinical signs of toxicity (weight loss vomiting, and
adverse hematology). The colostrum diet had significant positive
effects on markers of intestinal function in BUCY pigs (brush
border enzymes and hexose absorptive capacity), whereas the
effects on structural markers were limited or absent (villus
structure, intestinal weight, and plasma citrulline). Colostrum
also tended to reduce concentrations of proinflammatory cyto-
kines (IL-8 and IL-6). Finally, our results showed that colostrum
feeding of BUCY pigs may reduce cytotoxic liver injury, as
indicated by lower circulating concentrations of transaminases
and bilirubin. Collectively, we conclude that there is a potential to
improve chemotherapy-induced toxicity by inclusion of BC into
the enteral diet for such patients. More studies are required,
however, to define the optimal timing and amount of colostrum in
relation to different types of cytotoxic chemotherapies. In our
studies on children subjected to chemotherapy, supplementary BC
is provided during a limited time frame before and shortly after
chemotherapy (clinicaltrials.gov: NCT01766804).
BC is the milk produced in the first 1–2 d after parturition. It
contains a high amount of bioactive components, such as IgG,
TGFb, insulin-like growth factors, platelet-derived growth factor,
fibroblast growth factor, and epidermal growth factor, all known to
stimulate growth in mammalian cells in vitro and in vivo (11, 13).
BC has shown potential in reducing the severity of NEC in preterm
piglets (16), and it also preserves intestinal integrity and reduces
bacterial translocation in rats treated with diclofenac (44) and
inhibits NF-kB signaling in human colon cancer cell lines (45). In
our study, colostrum feeding did not prevent a reduction in serum
citrulline concentrations, relative to MR feeding. There were also
lower concentrations of serum citrulline and a trend toward
reduced intestinal mass in the Ctr-BC group vs. the Ctr-MR group.
These findings suggest that feeding exclusively colostrum for up to
11 d may be less than ideal. The relatively long period of exclusive
colostrum feeding in this study may also explain why we did not
detect a positive effect on structural intestinal variables in the
BUCY-BC group, but only on functional variables. We cannot
exclude the possibility that the diet effects in this study could also in
part result from a difference in the source of macronutrients
between diets. However, it is unlikely that a single component, such
as a cytokine, growth factor, or amino acid alone, can ameliorate
gastrointestinal toxicity in an effective manner (46). Actually it
might be the unique combination of growth factors, immune-
regulating cytokines, antimicrobial peptides, and specific nutrients
such as special proteins, amino acids, and milk fat molecules in BC
that mediate the observed effects (47). For the MR formula used in
this study, fats were mainly vegetable oils (not milk fats as in BC),
proteins were whey proteins plus nonmilk proteins (not IgG, casein,
and whey as in BC), and carbohydrates were mainly maltodextrins
(not lactose as in BC). For these reasons, the BC intervention diet
was compared to a formula diet containing the same overall energy
amount as the BC diet, and with formula ingredients that reflect
those often incorporated in enteral diets for tube-fed hospitalized
patients suffering from oral and gastrointestinal mucositis.
Previous investigations have demonstrated significant chemotherapy-
induced effects on the gut microbiota. These include decreased
bacterial diversity (48) and increased density of potentially pathogenic
bacteria, such asEscherichia, Clostridia, andEnterococci (17, 19, 48–
51), and decreased density of potentially beneficial bacteria, such as
Lactobacilli andBifidobacteria (19, 48, 49). The results of the present
study support these previous findings in that BUCY treatment
reduced microbial diversity in the small intestine. BUCY pigs with
oral mucositis tended to have more Escherichia in the small intestine
than did BUCYpigs without mucositis and, in our study, BUCYpigs
also hadmoreLactobacilli. The limited effects of diet on the intestinal
microbiota suggest that the BC effects on the mucosa are primarily
related to host responses via the trophic and immune-modulatory
properties of BC (51). However, we cannot exclude effects on
absolute bacterial abundance and we previously showed NEC to be
more closely related to bacterial load than to bacterial composition
(52). It is also possible that both diet andBUCY treatment affected the
density and diversity of microbiota specifically along the mucosal
lining. Finally, it is possible that compositional changes in the
colonic microbiota depend on the time after start of treatment,
because chemotherapy-induced dysbiosis may not be present until
several days or even weeks after chemotherapy (53, 54).
In conclusion, BC may reduce gastrointestinal complications
during myeloablative chemotherapy by preserving gastrointestinal
function and reducing inflammation. Further animal studies should
investigate the use of colostrum as a supplement to other diets and
in relation to different chemotherapy regimens and feeding periods
before and after treatment. As such, BC may become an important
adjunct dietary therapy to reduce chemotherapy-induced mucositis.
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